Caliway Biopharmaceuticals Co Ltd (6919) Stock Price & Analysis

6919 Stock Chart & Stats

NT$64.00-NT$2.60(-3.90%)

At close: Nov 06 12:30 AM EST

Day’s Range: TWD 61.20 - TWD 68.90
52-Week Range: TWD 59.90 - TWD 188.00
Previous Close: TWD 66.60
Volume: N/A
Average Volume (3M): 4.07M
Market Cap: TWD 99.66B
Enterprise Value: TWD 150.69B
Total Cash (Recent Filing): TWD 4.05B
Total Debt (Recent Filing): TWD 107.95M
Price to Earnings (P/E): ―
Beta: 0.62
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Low Recent Leverage

Very low recent leverage reduces the company’s near-term exposure to interest costs, refinancing pressure, and debt covenant constraints. This gives management greater flexibility to direct available resources toward therapeutic development, although it does not offset the need to fund ongoing losses.

Long-Term Revenue Progress

Revenue expansion across 2020–2025 and the 2025 rebound indicate that Caliway has generated commercial or development-related top-line progress over time. If sustained, this can broaden the company’s operating base and improve the potential for future scale as candidates advance.

Innovative Drug Development Focus

A focus on novel therapeutics gives Caliway exposure to potentially differentiated medicines rather than commoditized generic products. Advancing candidates through preclinical and clinical stages can create long-term intellectual-property and pipeline value if development milestones and clinical outcomes support commercialization.

Bears Say

Persistent Deep Losses

Recurring operating and net losses show that the current business has not yet achieved economic self-sufficiency. Even with year-over-year improvement, losses remain large relative to revenue, limiting internal reinvestment capacity and increasing dependence on successful future development or financing outcomes.

Structural Cash Burn

Sustained negative operating and free cash flow means the company is consuming cash to operate and develop its business rather than funding itself internally. Persistent burn can constrain pipeline investment and make additional capital requirements more important over the next several quarters.

Volatile Business Economics

Large swings in gross margin, assets, and equity make the company’s underlying economics and financial trajectory difficult to assess. This volatility reduces confidence in the durability of reported improvements and raises the risk that future results will remain uneven rather than scale predictably.

6919 FAQ

What was Caliway Biopharmaceuticals Co Ltd’s price range in the past 12 months?

Caliway Biopharmaceuticals Co Ltd lowest stock price was TWD 59.90 and its highest was TWD 188.00 in the past 12 months.

What is Caliway Biopharmaceuticals Co Ltd’s market cap?

Caliway Biopharmaceuticals Co Ltd’s market cap is TWD 99.66B.

When is Caliway Biopharmaceuticals Co Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Caliway Biopharmaceuticals Co Ltd’s earnings last quarter?

Caliway Biopharmaceuticals Co Ltd released its earnings results on Nov 11, 2026. The company reported -TWD 0.237 earnings per share for the quarter.

Is Caliway Biopharmaceuticals Co Ltd overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Caliway Biopharmaceuticals Co Ltd pay dividends?

Caliway Biopharmaceuticals Co Ltd does not currently pay dividends.

What is Caliway Biopharmaceuticals Co Ltd’s EPS estimate?

Caliway Biopharmaceuticals Co Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Caliway Biopharmaceuticals Co Ltd have?

Caliway Biopharmaceuticals Co Ltd has 1,557,200,800 shares outstanding.

What happened to Caliway Biopharmaceuticals Co Ltd’s price movement after its last earnings report?

Caliway Biopharmaceuticals Co Ltd reported an EPS of -TWD 0.237 in its last earnings report. Following the earnings report the stock price went up 6.311%.

Which hedge fund is a major shareholder of Caliway Biopharmaceuticals Co Ltd?

Currently, no hedge funds are holding shares in TW:6919

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description